

## **Bernard Davitian**

### **Vice President and Managing Director, Sanofi-Genzyme BioVentures**

Bernard Davitian has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. His track record includes, among others, the successful IPO of Transgene on the NASDAQ and Euronext in 1998 (\$100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction.

Bernard joined Sanofi in 2010 as Vice President, Deputy of Global Head, Business Development Corporate Licenses and was promoted to Vice President and Managing Director of SGBV in 2012. Prior to Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech Pharmaceuticals, and EVP & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO.

In addition to his SGBV-related Boards of Directors responsibilities, which include Unum Therapeutics, Lysosomal Therapeutics Inc, Proteostasis Therapeutics and Kahr Medical, Bernard also represents Sanofi on the Board of Directors of Warp Drive Bio. Bernard holds an MSc in Management (MBA equivalent) from EM Lyon Business School (France). He is also a Certified Public Accountant (CPA) and holds an executive M.B.A. (AMP program) from Wharton Business School.

